ATN-101 (Xirestomig)
Immune-responsive and 'Cold' Tumors (e.g., Melanoma, Colorectal Cancer)
Phase IActive
Key Facts
Indication
Immune-responsive and 'Cold' Tumors (e.g., Melanoma, Colorectal Cancer)
Phase
Phase I
Status
Active
Company
About Antennova
Antennova is a private, pre-revenue biotech advancing a clinical-stage pipeline of four novel oncology assets targeting key immune pathways. Its portfolio includes an ADC, a small molecule inhibitor, and bispecific/monoclonal antibodies, all designed with differentiation to overcome limitations of existing therapies, such as targeting low antigen expressors or reversing checkpoint inhibitor resistance. The company leverages deep immuno-oncology expertise to create a synergistic portfolio aimed at combination therapies for a broad range of solid tumors and hematologic malignancies.
View full company profile